Drug
Oral N-Acetylcysteine
Oral N-Acetylcysteine is a pharmaceutical drug with 3 clinical trials. Historical success rate of 33.3%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
2(67%)
Phase Distribution
Ph phase_2
1
33%
Ph early_phase_1
1
33%
Ph not_applicable
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)
Trials by Status
completed133%
terminated267%
Recent Activity
0 active trials
Showing 3 of 3
terminatednot_applicable
A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate
NCT00579995
terminatedearly_phase_1
The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow During Hypoxia and Normoxia
NCT01905696
completedphase_2
N-acetylcysteine Protects From Aminoglycosides Induced Nephrotoxicity
NCT00267384
Clinical Trials (3)
Showing 3 of 3 trials
NCT00579995Not Applicable
A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate
NCT01905696Early Phase 1
The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow During Hypoxia and Normoxia
NCT00267384Phase 2
N-acetylcysteine Protects From Aminoglycosides Induced Nephrotoxicity
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3